Gut microbiome and metabonomic profile predict early remission to anti-integrin therapy in patients with moderate to severe ulcerative colitis

Patients with ulcerative colitis (UC) have low response rates to anti-integrin medications, necessitating the identification of non-invasive biomarkers for predicting remission to anti-integrin therapy. The primary aims of this pilot study were to discover differences in the gut microbiome and metabonomics patterns between early remission and non-remission patients and to explore the diagnostic value in predicting clinical remission to anti-integrin therapy accurately.